Multiple Myeloma
Jul 23, 2024
CEPI Grants $41.3 Million to Valneva; Innovent Achieves Phase III Success for Mazdutide; GSK’s BLENREP Combination Therapies EMA Review Application; Darolutamide Phase III ARANOTE Trial; Roche’s SUSVIMO Shows Long-Term Efficacy
CEPI Grants $41.3 Million to Valneva to Enhance Global Access to First Chikungunya Vaccine The Coalition for Epidemic Preparedness Innovations and Valneva SE have expanded their partnership to enhance access to the world's first chikungunya vaccine, IXCHIQ®, in Low- and Middle-Income Countries (LMICs). CEPI will...
Read More...
Jul 23, 2024
Understanding High Risk Smoldering Multiple Myeloma: A Bridge Between MGUS and Multiple Myeloma
Smoldering Multiple Myeloma (SMM) is an asymptomatic condition that acts as an intermediate stage between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. First described by Kyle and Greipp in 1980, SMM typically affects individuals aged 50 to 70 and is usually diagnosed incidentally ...
Read More...
Jul 19, 2024
Multiple Myeloma: An Incurable B-cell Malignancy and A Vicious Cycle of Relapse
A cancer of plasma cells, a malignant plasma cell dyscrasia, Multiple Myeloma is a cancer that accumulates in the bone marrow leading to the number of healthy blood cells to plunge. The condition results in osteolysis due to an increase in osteoclastic and decreased osteoblastic activity. Multiple myeloma predom...
Read More...
Apr 08, 2024
Regeneron Presents Positive Pivotal Data on Linvoseltamab for Relapsed/Refractory Multiple Myeloma at AACR Annual Meeting 2024
Regeneron Pharmaceuticals unveiled promising results from the Phase I/II LINKER-MM1 trial of linvoseltamab in patients grappling with relapsed/refractory (R/R) multiple myeloma (MM) during the oral plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. Linvoselta...
Read More...
Mar 12, 2024
BeiGene’s BRUKINSA Gets FDA Accelerated Approval; GSK’s Positive Results in DREAMM-8 Phase III; Sandoz’s Denosumab Biosimilars FDA Approved; Terns Pharma’s TERN-701 Receives Orphan Drug Designation; Wegovy® Approved in US for Overweight Cardiovascular Risk; Travere Therapeutics Submits sNDA for FILSPARI IgAN Full Approval
BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alo...
Read More...
Jan 30, 2024
Merck’s KEYTRUDA as Adjuvant Therapy for RCC Patients; BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma for Multiple Myeloma; FDA Approves Dupixent for Eosinophilic Esophagitis; Juvena Receives FDA Orphan Drug Designation for JUV-161; European Commission Authorizes GSK’s Omjjara; ENHERTU Granted Priority Review in the US for for metastatic HER2-positive Solid Tumors
Merck’s KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Cancer (RCC) at an Increased Risk of Recurrence Following Nephrectomy Merck, also known as MSD beyond the United States and Canada, has revealed findings from the Phase III KEYNOTE-564 trial, which a...
Read More...
Dec 14, 2023
TALVEY’s Versatility Shines: Key Insights from MonumenTAL-2 Study Illuminate Effective Strategies in Relapsed/Refractory Multiple Myeloma
Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1014Abstract typeOral TALVEY (talquetamab) is a bispecific T-cell engaging antibody designed to target the CD3 receptor found on T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D). The findings presente...
Read More...
Dec 13, 2023
DARZALEX FASPRO Quadruplet Regimen Demonstrates Striking Advancements in Treatment Outcomes for Newly Diagnosed Multiple Myeloma Eligible for Transplantation
Date of Abstract presentation12th December 2023IndicationsMultiple MyelomaAbstract NumberLBA1Abstract typeOral The PERSEUS study is being conducted in collaboration with the European Myeloma Network as a sponsor. PERSEUS is an ongoing, randomized, open-label, Phase III study comparing the efficacy and safety of ...
Read More...
Dec 13, 2023
Cilta-cel Demonstrates Prolonged and Deep Responses across Advanced Treatment Lines, Signifying Potential in Early Lenalidomide-Refractory Multiple Myeloma
Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1063Abstract typeOral According to the findings presented at the ASH 2023, the CARTITUDE-4 trial included a cohort of 419 patients. As of the clinical cut-off, 99 patients in the CARVYKTI arm and 66 in the standard of care (...
Read More...
Dec 13, 2023
Cilta-Cel’s Prolonged Impact: Deep Responses and Safety Insights from Earlier Lines of Therapy in Multiple Myeloma
Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1021Abstract typeOral CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s T cells with a transge...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
